Next Gen Commercialization in Oncology and Hematology
Traditionally, manufacturers preparing to launch had three commercialization options: sell, out-license or launch on their own. However, these options may not be ideal for new oncology therapies. Similar to the way contract research organizations disrupted the market in the ’90s before becoming an industry staple, EVERSANA’s fourth commercialization option is the next phase of evolution for pharma.
EVERSANA™ COMPLETE Commercialization, our award winning model that disrupted the pharma industry, is the optimal solution for oncology drug manufacturers. With this innovative model, our partners optimize their investments, minimize risk and increase speed to market.
Key Benefits of Our Model:
- Delivers more value than traditional licensing or launching on your own.
- Activates a complete, ready-to-deploy, high-performance commercialization and distribution engine.
- Accelerates your product from early development to marketing, effectively impacting patient outcomes and beyond.
EVERSANA is uniquely positioned to address challenges in the oncology and hematology pipeline with agility and data-driven solutions. With an infrastructure based on product and patient needs, our commercialization model provides manufacturers the flexibility and expertise to customize their strategies and build functional service areas for a successful launch.
With one accountable commercialization partner to make decisions with, manufacturers can enable connectivity between services to manage costs, lower compliance and competitive risks and increase speed to launch in today’s complex market – and ultimately provide timely patient access.
True Financial Benefit
A recent study examined 10 real-world pharma launches and compared them to companies that embraced this new, innovative, scalable commercialization model. The study concluded that those who launched in the traditional model overspent by 23%, without any upside on launch success. Download the white paper to see an in-depth analysis of all launches and costs.
